Major Depressive Disorder: key endpoint results by drug
The key endpoints of Major Depressive Disorder trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Major Depressive Disorder page.
MADRS, change (acute) (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Ansofaxine hydrochloride | -19.9a | -14.6 | −5.3 | ansofaxine 160 mg · wk 8 | NCT04853407 Phase 3, primary |
| Brexpiprazole (Rexulti) | -8.2 | -6.7 | −1.5 | 2 mg · wk 6 · n 245 | NCT03697603 Phase 2/3, primary |
| Cariprazine (Vraylar) | -13.1 | -11.5 | −1.6 | 3 mg/Day · wk 6 · n 223 | NCT03738215 Phase 3, primary |
| Dextromethorphan/bupropion | 15.9 | 12.0 | +3.9 | wk 6 · n 156 | NCT04019704 Phase 3, primary |
| Esketamine | -15.7 | -12.4 | −3.3 | 84 mg · wk 0.14 · n 113 | NCT03097133 Phase 3, primary |
| Lumateperone | -14.7 | -9.8 | −4.9 | 42 mg · wk 6.14 · n 239 | NCT04985942 Phase 3, primary |
| Psilocybin (COMP360) | -12 | -6.8 | −5.2 | 25 mg · wk 3 · n 79 | NCT03775200 Phase 2, primary |
| Seltorexant | -12.9 | -10.5 | −2.4 | 20 mg · wk 6.14 · n 196 | NCT04533529 Phase 3, primary |
| Vortioxetine | -15.4 | -12.4 | −3.1 | 20 mg · wk 8 · n 164 | NCT02389816 Phase 3, primary |
Drugs checked with no result here: 9 not reported, 8 trial running, 5 not posted.
CGI-S, change (acute) (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Brexpiprazole (Rexulti) | -0.7 | -0.5 | −0.2 | 2 mg/Day · wk 12 · n 187 | NCT01360645 Phase 3, secondary |
| Cariprazine (Vraylar) | -1.3 | -1.1 | −0.2 | 3 mg/Day · wk 6 · n 223 | NCT03738215 Phase 3, secondary |
| Esketamine | -2 | -1 | −1 | 84 mg · wk 4 · n 113 | NCT02417064 Phase 3, secondary |
| Lumateperone | -1.6 | -0.9 | −0.7 | 42 mg · wk 6.14 · n 239 | NCT04985942 Phase 3, secondary |
| Pimavanserin | -1.4 | -1.1 | −0.3 | wk 5 · n 148 | NCT03968159 Phase 3, secondary |
| Seltorexant | -1.2 | -1.7 (Quetiapine XR) | — | wk 12 · n 38 | NCT03321526 Phase 2, secondary |
| Vortioxetine | -1.4 | -1.3 | −0.1 | 20 mg · wk 8 · n 146 | NCT02709655 Phase 3, secondary |
Drugs checked with no result here: 8 not posted, 8 not reported, 8 trial running.
MADRS response (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Brexpiprazole (Rexulti) | 23.5% | 14.7% | +8.8 | 2 mg/Day · wk 14 · n 187 | NCT01360645 Phase 3, secondary |
| Esketamine | 53.1% | 38.9% | +14.2 | 84 mg · wk 4 · n 98 | NCT02417064 Phase 3, secondary |
| Seltorexant | 35.4% | 22.9% | +12.5 | 20 mg · wk 6.14 · n 209 | NCT04533529 Phase 3, secondary |
| Vortioxetine | 50.6% | 36.6% | +14 | 20 mg · wk 8 · n 164 | NCT02389816 Phase 3, secondary |
Drugs checked with no result here: 8 not posted, 10 not reported, 9 trial running.
MADRS remission (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Brexpiprazole (Rexulti) | 14.4% | 8.4% | +6 | 2 mg/Day · wk 14 · n 187 | NCT01360645 Phase 3, secondary |
| Esketamine | 27.1% | 17.6% (Quetiapine Extended Release (XR) + Oral AD) | — | wk 8 · n 336 | NCT04338321 Phase 3, primary |
| Vortioxetine | 30.9% | 21.1% | +9.8 | 20 mg · wk 8 · n 164 | NCT02389816 Phase 3, secondary |
Drugs checked with no result here: 8 not posted, 10 not reported, 10 trial running.
Relapse (% of patients) (maintenance)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Brexpiprazole (Rexulti) | 22.5% | 20.6% | +1.9 | wk 26 · n 240 | NCT03538691 Phase 3, secondary |
| Vortioxetine | 15.2% | 30.2% | −15 | 5 or 10 mg · wk 64 · n 204 | NCT00596817 Phase 3, secondary |
Drugs checked with no result here: 8 not posted, 10 not reported, 11 trial running.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 31 approved or late-stage drugs with a featured trial in Major Depressive Disorder were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.